{"cited_by_count":655962,"description":"This cluster of papers focuses on the efficacy and resistance of various tyrosine kinase inhibitors, such as Imatinib, Dasatinib, and Nilotinib, in the treatment of Chronic Myeloid Leukemia (CML). The papers discuss molecular mechanisms of resistance, mutation analysis, leukemia stem cells, treatment discontinuation, and long-term outcomes of different targeted therapies.","display_name":"Chronic Myeloid Leukemia Treatments","domain_id":"4","external_ids":{"openalex":"https://openalex.org/T11215","wikipedia":"https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia"},"field_id":"27","id":"T11215","keywords":[{"display_name":"chronic myeloid leukemia","id":"chronic-myeloid-leukemia","score":0.5236,"url":"https://openalex.org/keywords/chronic-myeloid-leukemia"},{"display_name":"imatinib","id":"imatinib","score":0.3637,"url":"https://openalex.org/keywords/imatinib"},{"display_name":"BCR-ABL","id":"bcr-abl","score":0.5991,"url":"https://openalex.org/keywords/bcr-abl"},{"display_name":"Philadelphia chromosome","id":"philadelphia-chromosome","score":0.6068,"url":"https://openalex.org/keywords/philadelphia-chromosome"},{"display_name":"imatinib resistance","id":"imatinib-resistance","score":0.6058,"url":"https://openalex.org/keywords/imatinib-resistance"},{"display_name":"dasatinib","id":"dasatinib","score":0.3771,"url":"https://openalex.org/keywords/dasatinib"},{"display_name":"nilotinib","id":"nilotinib","score":0.6003,"url":"https://openalex.org/keywords/nilotinib"},{"display_name":"blast crisis","id":"blast-crisis","score":0.7286,"url":"https://openalex.org/keywords/blast-crisis"},{"display_name":"chronic phase","id":"chronic-phase","score":0.5559,"url":"https://openalex.org/keywords/chronic-phase"},{"display_name":"BCR-ABL1","id":"bcr-abl1","score":0.5623,"url":"https://openalex.org/keywords/bcr-abl1"},{"display_name":"BCR-ABL fusion gene","id":"bcr-abl-fusion","score":0.592,"url":"https://openalex.org/keywords/bcr-abl-fusion"},{"display_name":"chronic phase CML","id":"chronic-phase-cml","score":0.9063,"url":"https://openalex.org/keywords/chronic-phase-cml"},{"display_name":"tyrosine kinase inhibitor resistance","id":"tyrosine-kinase-inhibitor-resistance","score":0.4092,"url":"https://openalex.org/keywords/tyrosine-kinase-inhibitor-resistance"},{"display_name":"T315I mutation","id":"t315i-mutation","score":0.8387,"url":"https://openalex.org/keywords/t315i-mutation"},{"display_name":"molecular response","id":"molecular-response","score":0.4896,"url":"https://openalex.org/keywords/molecular-response"},{"display_name":"major molecular response","id":"major-molecular-response","score":0.9329,"url":"https://openalex.org/keywords/major-molecular-response"},{"display_name":"imatinib mesylate","id":"imatinib-mesylate","score":0.2815,"url":"https://openalex.org/keywords/imatinib-mesylate"},{"display_name":"cytogenetic response","id":"cytogenetic-response","score":0.7932,"url":"https://openalex.org/keywords/cytogenetic-response"},{"display_name":"complete cytogenetic response","id":"complete-cytogenetic-response","score":0.9333,"url":"https://openalex.org/keywords/complete-cytogenetic-response"},{"display_name":"accelerated phase","id":"accelerated-phase","score":0.7633,"url":"https://openalex.org/keywords/accelerated-phase"},{"display_name":"BCR-ABL tyrosine kinase inhibitors","id":"bcr-abl-tyrosine-kinase-inhibitors","score":0.5835,"url":"https://openalex.org/keywords/bcr-abl-tyrosine-kinase-inhibitors"},{"display_name":"ponatinib","id":"ponatinib","score":0.4631,"url":"https://openalex.org/keywords/ponatinib"},{"display_name":"treatment-free remission","id":"treatment-free-remission","score":0.7762,"url":"https://openalex.org/keywords/treatment-free-remission"},{"display_name":"Philadelphia chromosome-positive leukemia","id":"philadelphia-chromosome-positive-leukemia","score":0.6381,"url":"https://openalex.org/keywords/philadelphia-chromosome-positive-leukemia"},{"display_name":"bosutinib","id":"bosutinib","score":0.5766,"url":"https://openalex.org/keywords/bosutinib"}],"legacy_keywords":["Imatinib","BCR-ABL","Tyrosine Kinase Inhibitors","Resistance","Mutation","Leukemia Stem Cells","Molecular Response","Treatment Discontinuation","Dasatinib","Nilotinib"],"openalex_id":"https://openalex.org/T11215","source_created_date":"2024-01-23T15:27:09","source_updated_date":"2026-10-17T03:02:00","subfield_id":"2720","url":"/topics/T11215","works_api_url":"https://api.openalex.org/works?filter=topics.id:T11215","works_count":43989,"label":"Chronic Myeloid Leukemia Treatments","provider":"openalex","revision":"f6e0ffcb475b4e96","taxonomy_revision":"f050b5d4780b1289","title":"Chronic Myeloid Leukemia Treatments","kind":"topic-directory","aeo_cohort":"topic-directory","catalogue_revision":"f050b5d4780b1289","numeric_address":"36240765604768170","address_version":"morton4x16-v1","coordinates":[4,27,2720,11215],"answer_status":"Directory metadata; local answer requires separate source review","truth_status":"Subject descriptor, not a factual answer or a demonstrated knowledge gap","reviewed_answer":null}